Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004085 · ClinicalTrials.gov registry record · Phase 1
Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
A Phase 1 study, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00004085 is a Phase 1 study that has completed, run by Garden State Cancer Center at the Center for Molecular Medicine and Immunology. The registered enrollment target is 15 participants.
The verdict
NCT00004085, a Phase 1 study, has completed, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation in treating patients who have stage IV breast cancer.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- PROCEDURE autologous bone marrow transplantation
- RADIATION yttrium Y 90 monoclonal antibody MN-14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1998-05 |
| Phase | Phase 1 |
Sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology6 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004085
The ClinicalTrials.gov registry entry for NCT00004085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT00004085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004085 about?
NCT00004085 is a clinical study titled "Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effe...
What is the current status of trial NCT00004085?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1998-05.
What interventions are being tested in trial NCT00004085?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), autologous bone marrow transplantation (PROCEDURE), yttrium Y 90 monoclonal antibody MN-14 (RADIATION).
Who is sponsoring clinical trial NCT00004085?
This trial is sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.